

ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List  
药通中国1对1约会列表



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

公司代号	资产简介	资产阶段	Market Cap (USD)	Company Description	Asset code	Asset Indication	Mode of Action	Asset Description
AC3194	首个治疗实体瘤的氯毒素 CAR-T 疗法项目	Ph 1	27M	A clinical-stage cell therapy company committed to cure cancer, not just delay disease progression. Executives are experts in cell therapy and have been deeply involved in the development and commercialization of several FDA-approved CAR T programs including Abecma, Breyanzi, Yescarta and Tecartus.	AC3194-1	Glioblastoma	It exploits the ability of CLTX to recognise a receptor complex comprising membrane-bound matrix metalloproteinase 2 (MMP2) on malignant glioma cells.	CAR T-cells are manufactured from an autologous naïve/memory T cell (Tn/mem) selected starting population, using a lentiviral vector encoding the CLTX CAR.
AC3429	治疗急性缺血性脑卒中的潜在Best-in-class重组蛋白药物	Ph 2/3 Ph 2	31M	A U.S.-based company committed to improving the lives of people suffering serious diseases with initial focus on acute ischemic stroke (AIS) and chronic kidney disease (CKD).	AC3429-1	Acute ischemic stroke (AIS)	It locally activates nitric oxide and prostaglandins to selectively vasodilate arteries in area of ischemic penumbra to increase collateral blood flow to Improve stroke recovery, reducing the risk of brain infarct from arterial re-occlusion.	Recombinant KLK1 protein. FDA fast track designation.
AC3475	首款获批无需剂量调整的睾酮替代疗法口服药物	已上市	42M	A biopharmaceutical company focused on neuroendocrine and metabolic disorders using its proprietary drug delivery technologies.	AC3475-1	Deficiency or absence of endogenous testosterone.	Oral TRT option	The first and only approved oral TRT option in the U.S. that does not require dose titration.
AC3469	CD30 靶向的 Best-in-class ADC 用于治疗淋巴瘤	IND-ready		An antibody-drug conjugate company with a pipeline of next generation ADCs moving towards the clinic. Backed by Andera Partners, a leading European private equity Fund, Evotec, Fund+, and all old shareholders, including Bayern Kapital, BioMedPartners, Coparion, High-Tech Grunderfonds, OCCIDENT and Seventure Partners.	AC3469-1	Lymphomae: all CD30+ malignancies including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), Hodgkin's lymphoma (CHL) and others	Antibody drug conjugate (ADC) targeting CD30	A best-in-class, IND-ready ADC asset for the treatment of lymphoma targeting CD30.
AC3496	唯一一款针对急性痛风疼痛的局部治疗透皮乳膏	Ph 2a		A clinical-stage biotechnical company, which has created a breakthrough transdermal delivery platform for a wide range of clinical pipelines, including a series of New Chemical Entity (NCEs) projects with major pharmaceutical companies.	AC3496-1	Acute Gout	pH Modulation	The only topical transdermal ointment for acute gout.
	用于治疗实体瘤的pH调节剂的透皮制剂	Pre-clinical			AC3496-2	Solid Tumors	pH Modulation	A transdermal formulation for pH Modulation of Solid Tumors.
	氨甲酸透皮制剂, 适用于黄褐斑等色素沉着性疾病	Ph 1			AC3496-3	Melasma	Tranexamic acid	Transdermal preparation of tranexamic acid, suitable for pigmentation diseases such as melasma.
	现有注射用细胞溶解剂药物的透皮制剂, 用于分解脂肪以减少腰部脂肪	Ph 1			AC3496-4	Adipolysis	Cytolytic agent	A transdermal preparation of injectable cytolytic drugs used for flank fat reduction.
	现有口服免疫抑制剂药物的唯一透皮制剂	Pre-clinical			AC3496-5	Psoriasis	Immunosuppressant	The only transdermal preparation of existing oral immunosuppressive drugs
AC3431	每日口服一次的选择性黑素皮质激素激动剂	Ph 2a	1.5B	The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.	AC3431-1	RA/Nephrotic Syndrome	Oral selective melanocortin agonist	A once-daily oral selective melanocortin agonist.

ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List  
药通中国1对1约会列表



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD610C](https://jinshuju.net/f/nD610C)

公司代号	资产简介	资产阶段	Market Cap (USD)	Company Description	Asset code	Asset Indication	Mode of Action	Asset Description
AC3497	新一代光激活肿瘤疗法, 患者在门诊接受局部治疗, 光敏剂优先在肿瘤中积累, 然后被红光激活, 诱导肿瘤细胞死亡	Ph 2		A company dedicated to the development of novel cancer therapies for patients with unmet medical needs with unique platform strategy.	AC3497-1	Cutaneous Metastatic Breast Cancer (CMBC), Basal Cell Carcinoma Nevus Syndrome (BCCNS)	PDT induces elimination of diseased cells by immune response, apoptosis, antiangiogenesis and necrosis.	Second Generation photodynamic therapy with clinically validated superior results and materially reduced photosensitivity side effects.
AC3493	FIC 治疗人工关节感染的新型抗菌肽新药	Ph 1b		A U.S. base company aimed to discover and develop novel peptide therapeutics and through its biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing. The company is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation.	AC3493-1	Periprosthetic Joint Infection (PJI)	Designed-in features to disrupts bacterial membrane integrity by specifically interacting with lipids specific to bacterial membranes	First-in-class engineered antimicrobial peptide treating periprosthetic joint infections.
AC3259	新制剂巴氯芬鞘内给药项目	已上市		A fully integrated private company developing and commercializing sterile injectables as reformulated and repurposed generics for the emergency, ambulatory and critical care units of hospitals and care centers.	AC3259-7	Spasticity	An implantable pump delivers precise amounts of Baclofen directly to site of action at spinal cord via the cerebrospinal fluid.	Intrathecal treatment of severe spasticity with low incidence of side effects.
	新制剂氯普鲁卡因 3%眼科凝胶项目	NDA、DCP 申请中			AC3259-5	Ocular surface anesthesia and intraoperative pain management during short ophthalmologic procedures	Thickening agent; active molecule undergoes rapid enzymatic hydrolysis and has very low toxicity.	Ophthalmic gel for ocular surface anesthesia used in short procedures like cataract surgeries; FDA registration ongoing.
	获得专利的即用型去甲肾上腺素酒石酸盐配方	已上市			AC3259-6	Hypotension during surgery	A catecholamine sympathomimetic agent with a potent effects on $\alpha$ -adrenergic receptors and limited effect on $\beta$ -adrenergic receptors	Premix formulation of Norepinephrine; registered and on market product in many European countries.
AC3498	GD2 x CD3 双特异性抗体, 诱导 T 细胞杀死 GD2 阳性肿瘤细胞	Ph 1	180M	A commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, with a broad and advanced product pipeline, and rich experience in drugs targeting tumors that express GD2 and B7-H3, respectively.	AC3498-1	Pediatric GD2 positive tumors incl. NB and Relapsed/ Recurrent metastatic Small Cell Lung Cance	Bispecific antibody targeting GD2 (tumor) and CD3 to get T cell dependent cellular cytotoxicity (TDCC)	An anti-GD2xCD3 Monoclonal Antibody for development in pediatric GD2 positive tumors incl. NB and Relapsed/ Recurrent metastatic Small Cell Lung Cance.
AC3508	治疗肿瘤的第三代MnSOD类药物	Ph 2		The company is developing a new class of oncology therapeutics, redox active metalloporphyrins.	AC3508-1	Head and Neck Cancer	Redox active metalloporphyrin	A sub-cutaneous injection for oncologic conditions.
AC3509	M2缺陷型流感疫苗	Ph 2	49M	The company is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases. The company's lead candidate is M2SR, a supra-seasonal, live, single-replication, intranasal flu vaccine.	AC3509-1	Influenza virus A infection	M2SR H3N2 influenza vaccine	The vaccine candidate works differently, stimulating mucosal, humoral, and cellular immunity, and offering unprecedented efficacy against infection and illness across seven years of virus drift.
AC3510	每周一次的口服利培酮	Ph 3	23.5M	The company is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies for CNS, Opioid Addiction, Birth Control Pills, and Malaria.	AC3510-1	Schizophrenia	Innovative extended-release oral capsule technology	The first oral, ultra-long-acting, extended-release therapy that fundamentally changes the way people take their medicines, allowing patients to take their pills once a week instead of every day.

ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List  
药通中国1对1约会列表



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD610C](https://jinshuju.net/f/nD610C)

公司代号	资产简介	资产阶段	Market Cap (USD)	Company Description	Asset code	Asset Indication	Mode of Action	Asset Description
AC3511	预防化疗所致的粘膜炎	Ph 2	10.6M	The company developed a new technology to find drugs that block activity of cancer genes. This technology is being deployed to discover drugs for indications that have previously been considered "undruggable."	AC3511-1	Head and neck cancer		Using the company's Optimizing Marketed Drugs technology for the prevention/treatment of mucositis that occurs from front line cancer therapies.
AC3512	针对难治性慢性咳嗽、其他咳嗽过敏症状的P2X3受体拮抗剂	Ph 3	1.14B	The company is a clinical-stage biopharmaceutical company developing novel treatments for Refractory chronic cough (RCC) and other hypersensitivity indications.	AC3512-1	Refractory chronic cough	A highly selective P2X3 antagonist is being developed for RCC and other cough allergy indications.	A potent P2X3 receptor antagonist.
AC3513	一种治疗蕈样霉菌病的p-STAT3 抑制剂	Ph 2	35.5M	The company is a clinical-stage pharmaceutical company focused on developing a broad portfolio of drug candidates for the treatment of highly drug-resistant tumors and viruses.	AC3513-1	Sarcoma/CTCL Cutaneous T-Cell Lymphoma	Inhibits the activity of p-STAT3 and the growth of CTCL cell lines.	A synthetic compound that potently inhibits the activity of p-STAT3 and the growth of CTCL cell lines.
AC3514	个性化肿瘤疫苗	Ph 3	5M	The company develops an innovative portfolio of personalized therapeutic cancer vaccines.	AC3514-1	Stage IV Melanoma	Acts by stimulating TLPLDC (tumor lysate, particle load, dendritic cells).	The TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine.
AC3149	一种灌注疗法, 用于治疗急性失代偿性心力衰竭中的线粒体功能障碍	Ph 2		The company is a biopharmaceutical company focused on novel treatments for heart failure (HF) with mitochondrial dysfunction.	AC3149-1	Mitochondrial Dysfunction Heart Failure	Second-generation adenosine receptor agonist	An effective infusion therapy for the treatment of mitochondrial dysfunction in acute decompensated heart failure. Targets a type of mitochondrial dysfunction, restoring the energy output of heart muscle and improving its contractility.
AC3516	治疗复发或难治性急性髓系白血病的NK细胞疗法	Ph 2		A Korean company devoted to NK cell research and the commercialization of NK cell anti-cancer immunotherapy.	AC3516-1	R/R AML	NK cell-based anticancer immune cell therapy	NK cell-based anticancer immune cell therapy
AC3517	超声下子宫输卵管造影设备	已上市	13M	A biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are for permanent birth control and localized directional insemination for infertility.	AC3517-1	Infertility diagnosis	Real time evaluation of the fallopian tubes with ultrasound	The first FDA-cleared product that creates natural saline and air contrast and enables safe, reliable, and real time evaluation of the fallopian tubes with ultrasound. When performed with a uterine cavity assessment, a more comprehensive exam can be achieved from the comfort of the GYN's office.
AC3517	超声下子宫输卵管造影设备	已上市	13M	A biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are for permanent birth control and localized directional insemination for infertility.	AC3517-1	Infertility diagnosis	Real time evaluation of the fallopian tubes with ultrasound	The first FDA-cleared product that creates natural saline and air contrast and enables safe, reliable, and real time evaluation of the fallopian tubes with ultrasound. When performed with a uterine cavity assessment, a more comprehensive exam can be achieved from the comfort of the GYN's office.

**ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List**  
**药通中国1对1约会列表**



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

公司代号	资产简介	资产阶段	Market Cap (USD)	Company Description	Asset code	Asset Indication	Mode of Action	Asset Description
AC3518	由AI设计的治疗糖尿病、减重的小分子药物	IND-Enabling		The company has a one-stop AI-driven drug discovery platform. Within a few months of its establishment, the company has carried out commercial cooperation with a number of listed pharmaceutical companies and has been recognized.	AC3518-1	Diabetes, weight loss	GLP-1R agonist	Potential best in class Small molecule GLP-1R
AC3519	治疗骨质疏松和其他骨质流失疾病的人源化抗硬骨素单克隆抗体	Ph 1	210M	A global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing.	AC3519-1	Postmenopausal osteoporosis, osteoporosis	Sclerostin mAb	A humanized anti-sclerostin mAb, for the potential sc and iv treatment of postmenopausal osteoporosis and other bone loss diseases.

**Contact us**

Ms. Joanna Xu, Sr. BD Manager  
[zxu@yafocapital.com](mailto:zxu@yafocapital.com)  
[www.yafocapital.com](http://www.yafocapital.com)

**Join Us at ACCESS CHINA**

Ms. Wendi Xiang, VP  
[wxiang@yafocapital.com](mailto:wxiang@yafocapital.com)  
[BioToChina.org](http://BioToChina.org)